Drug treatments for adjuvant chemotherapy in breast cancer: Recent trials and future directions Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms

abstract

  • Adjuvant chemotherapy with anthracycline-based regimens has been proven to decrease the risk of relapse and cancer-related mortality in women with early-stage breast cancer. The taxanes, paclitaxel and docetaxel, have been incorporated into several adjuvant chemotherapy regimens in recent studies. Some of these trials have matured and demonstrated a definitive benefit with the use of taxanes. The available studies reveal that the addition of a taxane after an anthracycline or the substitution of a taxane into a three-drug regimen, such as docetaxel, doxorubicin and cyclophosphamide, clearly demonstrate a benefit for taxanes in the adjuvant treatment of breast cancer. The toxicities of the taxanes are generally acceptable. Targeted therapy, such as with trastuzumab, has demonstrated a large benefit that previously has never been seen in adjuvant chemotherapy trials, and thus, should now be part of the standard in the treatment of HER-2/neu positive breast cancer. Newer agents are on the horizon.

publication date

  • March 2006

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1586/14737140.6.3.427

PubMed ID

  • 16503859

Additional Document Info

start page

  • 427

end page

  • 36

volume

  • 6

number

  • 3